Skip to main content

Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure.

Publication ,  Journal Article
Cooper, LB; Hammill, BG; Peterson, ED; Pitt, B; Maciejewski, ML; Curtis, LH; Hernandez, AF
Published in: Circ Cardiovasc Qual Outcomes
January 2017

BACKGROUND: Heart failure guidelines recommend routine monitoring of serum potassium, and renal function in patients treated with a mineralocorticoid receptor antagonist (MRA). How these recommendations are implemented in high-risk patients or according to setting of drug initiation is poorly characterized. METHODS AND RESULTS: We conducted a retrospective cohort study of Medicare beneficiaries linked to laboratory data in 10 states with prevalent heart failure as of July 1, 2011, and incident MRA use between May 1 and September 30, 2011. Outcomes included laboratory testing before MRA initiation and in the early (days 1-10) and extended (days 11-90) post-initiation periods, based on setting of drug initiation and the presence of renal insufficiency. Additional outcomes included abnormal laboratory results and adverse events proximate to MRA initiation. Of 10 443 Medicare beneficiaries with heart failure started on an MRA, 19.7% were initiated during a hospitalization. Appropriate follow-up laboratory testing across all time periods occurred in 25.2% of patients with inpatient initiation compared with 2.8% of patients begun as an outpatient. Patients with chronic kidney disease had higher rates of both hyperkalemia and acute kidney failure in the early (1.3% and 2.7%, respectively) and extended (5.6% and 9.8%, respectively) post-initiation periods compared with those without chronic kidney disease. CONCLUSIONS: Patients initiated on MRA therapy as an outpatient had extremely poor rates of guideline indicated follow-up laboratory monitoring after drug initiation. In particular, patients with chronic kidney disease are at high risk for adverse events after MRA initiation. Quality improvement initiatives focused on systems to improve appropriate laboratory monitoring are needed.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circ Cardiovasc Qual Outcomes

DOI

EISSN

1941-7705

Publication Date

January 2017

Volume

10

Issue

1

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Time Factors
  • Risk Factors
  • Risk Assessment
  • Retrospective Studies
  • Renal Insufficiency
  • Practice Patterns, Physicians'
  • Practice Guidelines as Topic
  • Potassium
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cooper, L. B., Hammill, B. G., Peterson, E. D., Pitt, B., Maciejewski, M. L., Curtis, L. H., & Hernandez, A. F. (2017). Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. Circ Cardiovasc Qual Outcomes, 10(1). https://doi.org/10.1161/CIRCOUTCOMES.116.002946
Cooper, Lauren B., Bradley G. Hammill, Eric D. Peterson, Bertram Pitt, Matthew L. Maciejewski, Lesley H. Curtis, and Adrian F. Hernandez. “Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure.Circ Cardiovasc Qual Outcomes 10, no. 1 (January 2017). https://doi.org/10.1161/CIRCOUTCOMES.116.002946.
Cooper LB, Hammill BG, Peterson ED, Pitt B, Maciejewski ML, Curtis LH, et al. Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. Circ Cardiovasc Qual Outcomes. 2017 Jan;10(1).
Cooper, Lauren B., et al. “Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure.Circ Cardiovasc Qual Outcomes, vol. 10, no. 1, Jan. 2017. Pubmed, doi:10.1161/CIRCOUTCOMES.116.002946.
Cooper LB, Hammill BG, Peterson ED, Pitt B, Maciejewski ML, Curtis LH, Hernandez AF. Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. Circ Cardiovasc Qual Outcomes. 2017 Jan;10(1).

Published In

Circ Cardiovasc Qual Outcomes

DOI

EISSN

1941-7705

Publication Date

January 2017

Volume

10

Issue

1

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Time Factors
  • Risk Factors
  • Risk Assessment
  • Retrospective Studies
  • Renal Insufficiency
  • Practice Patterns, Physicians'
  • Practice Guidelines as Topic
  • Potassium